What is carotid artery disease and how does TCAR prevent strokes?

Carotid artery stenosis is atherosclerotic narrowing of the internal carotid arteries — the main blood vessels supplying the brain. Stroke risk: carotid plaques can rupture, sending emboli (clot/plaque fragments) to the brain causing ischemic stroke; the degree of stenosis correlates with stroke risk — severe stenosis (greater than 70%) carries higher risk; symptomatic patients (those who have had a TIA or minor stroke) have substantially higher near-term stroke risk than asymptomatic patients. Treatment options: Medical management — statins, antiplatelet therapy, blood pressure control; for moderate stenosis or lower-risk patients, medical management alone may be preferred. Carotid endarterectomy (CEA) — open surgery to remove the atherosclerotic plaque from the carotid artery; gold standard for over 50 years; well-proven efficacy; procedural risks include cranial nerve injury, neck wound complications, general anesthesia risks in high-surgical-risk patients. Transfemoral carotid stenting (CAS) — catheter-based stenting through the femoral artery (groin) into the carotid; avoids open surgery; risk of emboli dislodging during manipulation and traveling to the brain is a concern; embolic protection devices are used. TCAR mechanism: Silk Road Medical's TCAR makes a small incision directly in the carotid artery in the neck; flow reversal is established by temporarily reversing blood flow (carotid blood flows away from the brain into a filter outside the body and returned to the femoral vein); stent placement occurs during flow reversal; any debris dislodged during stenting is carried away from the brain rather than toward it; flow is restored after stenting; the brain is protected during the riskiest phase of the procedure.

What is the capital equipment plus consumables model in medical devices and why does it matter?

The capital equipment plus consumables model is a common medical device business structure where: the capital equipment component provides initial device placement (e.g., AquaBeam system, surgical robot, catheterization lab equipment) at high upfront cost; the consumables component provides recurring revenue from single-use disposable components used in each procedure (e.g., surgical procedure kits, catheter sets, single-use tips). Why this model is attractive for medical device companies: recurring revenue stream — after a capital sale, each procedure generates recurring consumable revenue without another capital sales effort; the consumable revenue is somewhat predictable (based on the installed base and procedure volume); switching costs — once a hospital or surgeon is trained on a specific system, the procedural familiarity and existing capital investment creates inertia against switching; capital equipment creates a 'razor and blades' like business where initial placement drives years of consumable sales. For Procept (PRCT): the AquaBeam system is the capital equipment; single-use hydrodissection kits (the waterjet procedure kit) are the consumables used in every Aquablation procedure; Procept grows by placing more AquaBeam systems and increasing procedure volume (utilization) per installed system. For Silk Road (SILK): the ENROUTE Transcarotid Stent System (stent plus neuroprotection catheter set) is primarily a disposable procedure system rather than capital equipment; SILK's revenue is largely consumable-based (charged per TCAR procedure); growth depends on TCAR procedure volume across a network of trained surgeons.

How does robotic guidance improve Aquablation outcomes compared to manual BPH surgery?

Traditional BPH surgery (TURP) requires the surgeon to manually resect prostate tissue using a resectoscope while visualizing through a camera — the surgeon simultaneously controls the resection tool and assesses tissue boundaries in real-time; surgical technique varies significantly between surgeons; tissue at the periphery of the prostate (where nerves controlling ejaculation and erectile function are located) may be inadvertently damaged by less experienced surgeons or in complex anatomies. AquaBeam's robotic advantages: imaging integration — before Aquablation, the surgeon performs a 3D ultrasound of the prostate; this creates a precise 3D map of the prostate anatomy including the boundaries of tissue to be removed and structures to be avoided (sphincter, verumontanum — the landmark indicating the ejaculatory structures). Planned resection — the surgeon plans exactly which tissue regions will be resected and defines safety margins on the ultrasound image before any resection occurs. Autonomous execution — the AquaBeam robot executes the planned resection according to the pre-programmed path; the surgeon does not manually guide the waterjet during the resection; the robot maintains the planned boundaries even if the prostate moves slightly. Outcomes: because the robot executes the pre-planned path consistently and respects the planned margins around ejaculatory structures, Aquablation's rate of retrograde ejaculation (the most common sexual side effect of BPH surgery) is lower than TURP in randomized trials; surgeon-to-surgeon variability is reduced because the robot executes the planned resection regardless of the surgeon's manual dexterity.

Data as of: September 28, 2026

brimindinvest.com / compare / prct-vs-silkLIVE

PRCT

PROCEPT BioRobotics Corporation · Healthcare - Surgical Robotics

$17.20

-18.37% this month

VERSUS

COMPARE

SILK

Silk Road Medical, Inc. · Healthcare - Vascular Interventional Devices

N/A

N/A this month

Comparison scoreboard

MIXED SETUP

AI Scorei

PRCT 23.8

SILK N/A

1Y Returni

PRCT -53.54%

SILK N/A

Fwd P/Ei

PRCT -19.05

SILK N/A

Target Up.i

PRCT -1.52%

SILK N/A

Op. Margini

PRCT -32.05%

SILK N/A

Metrics last refreshed: 9/28/2026

Quick take

PRCT vs SILK Stock Comparison: AI Score, Valuation, Performance and Upside

ShareX LinkedIn Reddit Facebook WhatsApp

PRCT (Procept BioRobotics) and SILK (Silk Road Medical) are both growth-stage commercial medical device companies with robotic/device innovations addressing specific surgical challenges — Procept's AquaBeam robotic water-jet system treats BPH with a differentiated sexual function preservation profile, while Silk Road Medical's TCAR provides a minimally invasive carotid stenting approach designed to reduce stroke risk during carotid revascularization. Both companies grow through capital equipment placements followed by recurring consumable/procedure revenue.

PRCT vs SILK is robotic urology device for BPH treatment with superior side effect profile (Procept's AquaBeam system using image-guided waterjet to remove prostate tissue with better ejaculatory function preservation than TURP or laser surgery, growing through hospital AquaBeam system installations) versus minimally invasive vascular device for carotid artery disease with direct cerebral protection (Silk Road Medical's ENROUTE TCAR system providing transcarotid carotid stenting with flow reversal neuroprotection as a less invasive alternative to carotid endarterectomy) — robotics-enabled urology versus innovative vascular access technique.

Live analysis · updated 9/28/2026

PRCT and SILK are closely matched — they split the tracked metrics evenly.

Normalized 1Y performance

PRCT

SILK

Not enough data to chart yet.

Recent returns

PRCT

SILK

Analyst price targets & sentiment

Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.

PRCT

Price target range

analyst mean$21.64
current price$17.20

-1.5% upside to analyst mean

SILK

Price target data unavailable

N/A

Who should consider this stock?

PRCT may suit investors who:

Believe Aquablation's clinical advantages (preserved sexual function, equivalent symptom improvement to gold-standard TURP) will drive continued adoption as sexually active BPH patients increasingly seek surgical treatment that doesn't compromise sexual function
Value Procept's robotics-based business model creating capital equipment plus recurring consumable revenue with high switching costs once AquaBeam systems are placed and surgeons are trained
See the large underserved BPH market (hundreds of millions of men globally with symptoms, many managed medically) as providing long runway for procedure volume growth if Aquablation's side effect advantages drive more men to choose surgical intervention

SILK may suit investors who:

Believe TCAR's clinical data showing low stroke rates with direct neuroprotection provides a compelling case for vascular surgeons to adopt TCAR for higher-risk-for-CEA carotid stenosis patients
Value Silk Road Medical's first-mover position in TCAR and established vascular surgery relationships as a durable competitive advantage in the carotid revascularization procedure market
See the ongoing refinement of carotid stenosis treatment guidelines and growing physician awareness of TCAR's safety profile as drivers of continued procedure volume growth from a relatively small but established commercial base

Performance & AI score

Performance & AI score
Metric	PRCT	SILK
AI scorei	23.8	N/A
AI ranki	#3439	N/A
Latest closei	$17.20	N/A
1M returni	-18.37%	N/A
6M returni	-34.75%	N/A
1Y returni	-53.54%	N/A

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

$10,000 invested — hypothetical growth (dividends reinvested)
Period	PRCT	SILK
1Y ago	$4.65K (-53.5%) started 2025-09-25	N/A
5Y ago	$4.55K (-54.5%) started 2021-09-27	N/A
10Y ago	$4.1K (-59.0%) started 2021-09-15	N/A

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Valuation & upside potential
Metric	PRCT	SILK
Market capi	$1.25B	N/A
Trailing P/Ei	N/A	N/A
Forward P/Ei	-19.05	N/A
Price/Salesi	N/A	6.31
EV/Revenuei	3.10	N/A
Analyst targeti	$21.64	N/A
Target upsidei	-1.52%	N/A

Growth, profitability & risk

Growth, profitability & risk
Metric	PRCT	SILK
Revenue growthi	19.30%	N/A
Earnings growthi	N/A	N/A
EPS growthi	N/A	N/A
FCF margini	-14.52%	N/A
Operating margini	-32.05%	N/A
Profit margini	-32.53%	N/A
ROIC proxyi	-30.24%	N/A
Return on equityi	-30.24%	N/A
Dividend yieldi	N/A	N/A
Payout ratioi	0.00%	N/A
Dividend growth streaki	N/A	N/A
Betai	0.89	2.21
Debt/equityi	22.79	N/A
Current ratioi	6.55	N/A
Quick ratioi	5.23	N/A

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

PRCT max drawdowni54.92%

SILK max drawdowniN/A

PRCT max wkly dropi28.12%

SILK max wkly dropiN/A

5Y risk snapshot

PRCT max drawdowni83.22%

SILK max drawdowniN/A

PRCT max wkly dropi28.12%

SILK max wkly dropiN/A

10Y risk snapshot

PRCT max drawdowni83.22%

SILK max drawdowniN/A

PRCT max wkly dropi28.12%

SILK max wkly dropiN/A

Performance metrics by period

Performance metrics by period
Period	Metric	PRCT	SILK
1Y	Growthi	-53.54%	N/A
	CAGRi	-53.56%	N/A
	Volatilityi	63.10%	N/A
	Sharpe ratioi	-0.97	N/A
	Sortino ratioi	-1.36	N/A
	Max drawdowni	54.92%	N/A
	Current drawdowni	53.54%	N/A
	Avg drawdowni	27.52%	N/A
	Ulcer Indexi	31.12%	N/A
	Max daily dropi	15.12%	N/A
	Max wkly dropi	28.12%	N/A
5Y	Growthi	-54.47%	N/A
	CAGRi	-14.58%	N/A
	Volatilityi	64.33%	N/A
	Sharpe ratioi	0.00	N/A
	Sortino ratioi	0.00	N/A
	Max drawdowni	83.22%	N/A
	Current drawdowni	82.70%	N/A
	Avg drawdowni	34.71%	N/A
	Ulcer Indexi	42.48%	N/A
	Max daily dropi	25.31%	N/A
	Max wkly dropi	28.12%	N/A
10Y	Growthi	-58.99%	N/A
	CAGRi	-16.25%	N/A
	Volatilityi	64.68%	N/A
	Sharpe ratioi	-0.03	N/A
	Sortino ratioi	-0.04	N/A
	Max drawdowni	83.22%	N/A
	Current drawdowni	82.70%	N/A
	Avg drawdowni	34.60%	N/A
	Ulcer Indexi	42.36%	N/A
	Max daily dropi	25.31%	N/A
	Max wkly dropi	28.12%	N/A

AI Prediction Signali

Members only

Next 5 trading days

PRCT

+2.8%BUY

SILK

+1.1%HOLD

Next 30 trading days

PRCT

+6.4%BUY

SILK

+3.2%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Business comparison

Business comparison
Category	PRCT	SILK
Company	PROCEPT BioRobotics Corporation	Silk Road Medical, Inc.
Sector	Healthcare	Healthcare - Vascular Interventional Devices
Industry	Medical Devices	N/A
Core business	PROCEPT BioRobotics is a commercial-stage robotics company focused on urology, specifically the treatment of benign prostatic hyperplasia (BPH — enlarged prostate). Procept's AquaBeam Robotic System performs Aquablation — a novel surgical technique that uses a robotically-controlled, image-guided high-pressure waterjet to precisely resect enlarged prostate tissue. Aquablation is performed under ultrasound and cystoscope guidance, with the robotic system executing the planned tissue removal autonomously following the surgeon's path plan; the waterjet removes tissue without heat, preserving the delicate tissue surrounding the prostate and potentially improving rates of preserved sexual function versus other surgical BPH treatments. Procept went public in September 2021.	Silk Road Medical is a commercial-stage medical device company focused on the treatment of carotid artery disease using Transcarotid Artery Revascularization (TCAR). TCAR is a minimally invasive procedure to treat carotid artery stenosis (narrowing of the carotid arteries supplying the brain) — a leading cause of stroke. The traditional treatment options are carotid endarterectomy (CEA — open surgical removal of plaque) or transfemoral carotid artery stenting (CAS — catheter-based stenting through the leg artery). TCAR uses Silk Road's ENROUTE Transcarotid Stent System and ENROUTE Neuroprotection System: surgeons make a small incision directly in the carotid artery in the neck (transcarotid access), temporarily reverse blood flow to prevent debris from reaching the brain, place a carotid stent, and then restore blood flow — a technique designed to reduce the stroke risk during carotid intervention.
Investor focus	Investors track Procept's AquaBeam system placements (number of robotic systems installed at urology practices and hospitals), Aquablation procedure volume growth (procedures performed per installed system), revenue and gross margin trajectory, and the clinical differentiation versus alternative BPH surgical treatments.	Investors track Silk Road's TCAR procedure volume growth (procedures performed), ENROUTE system utilization at vascular surgery centers and hospitals, and the adoption of TCAR as an alternative to traditional CEA or transfemoral carotid stenting among vascular surgeons and neurologists.

PRCT strengths

Aquablation is clinically differentiated with superior sexual function preservation evidence — clinical data from WATER trials shows Aquablation achieves equivalent urinary symptom improvement to TURP (the gold standard BPH surgery) while significantly better preserving ejaculatory and erectile function; this side effect profile is important for sexually active BPH patients
Large and underserved BPH surgical market — approximately 600 million men globally have BPH symptoms; approximately 8 million men have moderate-to-severe BPH; despite multiple treatment options, a majority of severely symptomatic patients manage with medications rather than surgery; improving surgical outcomes may expand the surgical treatment market
Robotics/AI-assisted surgery creates a capital-equipment-plus-consumables business model with high switching costs — once an AquaBeam system is installed and surgeons are trained, switching costs are high; consumable (single-use) procedure kits provide recurring revenue per procedure; this creates a sticky customer relationship model

SILK strengths

TCAR provides a less invasive carotid treatment with direct neuroprotection — TCAR's transcarotid approach with flow reversal provides direct cerebral protection while placing the carotid stent; clinical data (ROADSTER trials) shows low stroke rates comparable to carotid endarterectomy; TCAR avoids the open neck surgery trauma of CEA and the embolic risk of transfemoral CAS
Growing adoption driven by vascular surgery and interventional radiology interest in minimally invasive techniques — TCAR has been adopted by thousands of surgeons; the ROADSTER clinical trial results have been published in major journals; the SVS (Society for Vascular Surgery) has incorporated TCAR into its guidelines
Carotid disease is a high-consequence indication driving physician willingness to adopt new techniques — carotid stenosis is a leading cause of stroke; physicians managing these patients are motivated to adopt techniques that reduce procedural stroke risk; TCAR's neuroprotection mechanism is clinically intuitive

Risks to watch — PRCT

Capital equipment placement requires significant hospital/ASC investment decisions — AquaBeam systems are expensive capital equipment; hospitals and ASCs must see compelling procedure volume projections to justify capital investment; economic downturns or capital budget freezes slow placement growth
Competition from other BPH surgical treatments is strong — TURP (monopolar/bipolar), laser prostatectomy (HoLEP, GreenLight), Rezum water vapor therapy (Boston Scientific), UroLift (Teleflex), and Optilume BPH compete for BPH surgical market share; Aquablation must sustain clinical differentiation narrative
Growing procedure volume requires growing trained surgeon base — each new AquaBeam system placement requires surgeon training; building surgeon training programs at scale requires Procept's sales force investment

Risks to watch — SILK

TCAR faces competition from established CEA (carotid endarterectomy) — CEA is the gold standard with decades of safety data; many vascular surgeons are highly skilled at CEA and do not see sufficient clinical reason to change; penetrating the established surgical standard is always challenging
Carotid stenting market is relatively small — carotid revascularization is a specialized procedure volume segment; total annual U.S. carotid revascularization cases are approximately 100,000-130,000 per year (both CEA and CAS combined); market size limits the absolute revenue potential versus larger device markets
Medical management of carotid disease has improved — statins and antiplatelet therapy have reduced the stroke risk of asymptomatic carotid stenosis; evolving guidelines may narrow the carotid stenosis patient population that benefits from intervention, reducing the addressable surgical volume

Frequently asked questions

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland — an extremely common condition in aging men. Prevalence: approximately 50% of men in their 50s and 90% of men in their 80s have histological evidence of BPH; about half of men with BPH develop lower urinary tract symptoms (LUTS). Symptoms: BPH compresses the urethra (which runs through the prostate) and bladder neck, causing: weak urine stream, urinary frequency (including nocturia — nighttime urination), incomplete bladder emptying, urinary urgency, difficulty starting urination. BPH treatment ladder: Watchful waiting — mild symptoms managed with lifestyle modifications; Alpha-blockers (tamsulosin/Flomax, silodosin/Rapaflo) — relax prostate smooth muscle, improving urine flow; 5-alpha reductase inhibitors (finasteride, dutasteride) — shrink the prostate by reducing DHT; combination therapy — both drug classes together. Minimally invasive procedures: Rezum (Boston Scientific) — water vapor thermal ablation of prostate tissue; UroLift (Teleflex) — permanent implants that lift and hold enlarged prostate lobes away from the urethra; GreenLight laser photovaporization — laser ablation of prostate tissue. Surgical procedures: TURP (transurethral resection of the prostate) — the gold standard for decades; HoLEP (holmium laser enucleation) — highly effective but technically demanding; Aquablation (PROCEPT) — robotic water-jet resection with better sexual function preservation.

Interactive comparison engine

Compare more than two at a time

This page is a fixed writeup on PRCT and SILK. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.

Up to 5 tickers at once

Add three more names beside PRCT and SILK, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.

Scoreboard verdict

AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.

Full risk suite

Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.

Correlation heatmap

Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.

Valuation vs profitability

A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.

Holdings overlap and CSV export

For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.

Open PRCT vs SILK in the engine See what's included

Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

More comparisons